For further information: TRADED: NYSE (IEX) EX-99.1 Investor Contact: Wendy Palacios Vice President FP&A and Investor Relations (847) 498-7070 IDEX REPORTS SECOND QUARTER RESULTS AND UPDATES 2024 OUTLOOK Second Quarter 2024 Highlights (All comparisons are against the second quarter of 2023 unless otherwise noted) • Sales of $807 million, down 5% overall and 4% organically • Reported diluted EPS of $1.86, up 2%, and adjusted diluted EPS of $2.06, down 6%, exceeding second quarter expectations • Operating cas ...

IDEX Corporation's (IEX) second-quarter 2024 adjusted earnings of $2.06 per share surpassed the Zacks Consensus Estimate of $2.04. The bottom line decreased approximately 6% from the year-ago quarter's earnings of $2.18 per share. However, it exceeded management's projection of $2.00-$2.05 per share. Revenue Details IDEX's net sales of $807.2 million missed the Zacks Consensus Estimate of $831 million. The top line also decreased 5% year over year. Organic sales decreased 4% year over year. Foreign currency ...

Idex (IEX) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $2.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 0.98%. A quarter ago, it was expected that this maker of the Jaws of Life device and other engineered products would post earnings of $1.75 per share when it actually produced earnings of $1.88, delivering a surprise of 7.43% ...

IDEX Corporation (IEX) is scheduled to release second-quarter 2024 results on Jul 31, after market close. The Zacks Consensus Estimate for second-quarter earnings has remained steady in the past 60 days. The company has an impressive earnings surprise history, having outperformed the consensus estimate in each of the preceding four quarters, the average surprise being 6.3%. The consensus estimate for revenues is pegged at $830.8 million, indicating a decline of 1.8% from the year-ago quarter's reported figu ...

Image Source: Zacks Investment Research Expansion Efforts: The company solidified its product portfolio and leveraged business opportunities through asset additions. Acquired assets boosted its sales by 1% in the first quarter of 2024. In December 2023, IDEX acquired advanced material science solutions provider STC Material Solutions. This acquisition expanded its expertise in material sciences and offered significant opportunities to collaborate with other IDEX-critical components businesses on comprehensi ...

The board of directors of IDEX Biometrics ASA has resolved to issue 13,207,430 incentive subscription rights to 56 employees and individual contractors in the IDEX Biometrics group. The grant was made under the company's 2024 incentive subscription rights plan as resolved at the annual general meeting on 16 May 2024. The exercise price of the subscription rights is NOK 1.45 per share. The SRs vest by 1/3 per year over three years. The SRs expire on 16 May 2029. Following the company's recent restructuring i ...

Nordroden/iStock via Getty Images I highlighted IDEX's (NYS)E:IEX) weak growth in Health & Science Technologies segment in my previous coverage published in February 2024. The company released its Q1 FY24 result on April 23rd and reaffirmed its full-year guidance. While I acknowledge that the Health & Science Technologies will continue to face challeneys in FY24, IDEX's order growth has already started to moderate. I reiterate 'Buy' rating with a fair price target of $220 per share. Order Moderation In Q1 F ...

AuthenTrend, based out of Taiwan, focuses on digital document and identity verification. With a global reach and a strong presence in Asia, AuthenTrend provides a new generation of fingerprint-enabled card type security keys – ATKey.Card NFC x Surface Pro 10. These biometric cards support both contact and contactless FIDO2 passwordless login and take the login experience to the next level – secure and seamless. AuthenTrend provides FIDO2-certified biometric access card solutions to consumers and enterprises ...

All other resolutions were passed as proposed by the board, with an update as regards dates in item 4 on the agenda, Subsequent offering. At agenda item 5 Issue of warrants, the extraordinary general meeting resolved to issue warrants to investors participating in the Private Placement (both Tranche 1 and Tranche 2) and the Subsequent Offering. The number of warrants which may be issued shall be one warrant for each share subscribed for and allocated in the Private Placement or the Subsequent Offering. The ...

Management remains committed to rewarding shareholders through dividend payouts and share buybacks. For instance, in the first quarter of 2024, it paid dividends of $48.5 million. Also, in 2023, it distributed dividends of $190.7 million and repurchased common stocks worth $24.2 million. It announced a hike of 7.8% in its quarterly dividend rate in May 2024. However, weakness in the Health & Science Technologies (HST) segment due to softness in the life sciences, analytical instrumentation, semiconductor an ...